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Abstract
Objective Our objective was to evaluate the life-long
safety profile of gene therapy using retroviral (non-repli-
cating) vectors (nRCR), or cell products in 127 subjects
with hemophilia, human immunodeficiency virus (HIV), or
cancer, previously treated with such gene therapy.
Methods We assessed the occurrence of serious adverse
events (SAEs), deaths and presence of replication compe-
tent retrovirus (RCR).
Results A total of 23 subjects remained until the data cut-
off date of 31 July 2013 and provided safety information of
up to 18 years. Of the 104 subjects who discontinued, the
primary reason was loss to follow-up (47.2 %; n = 60).
The follow-up period for the 60 subjects lost to follow-up
was 7–10 years. A total of 41 subjects experienced at least
one SAE, and 15 subjects died. We reviewed SAEs and
cause of death (none related to the active therapy), but no
evidence was found for safety signals related to new
malignancy or neurologic, rheumatological, autoimmune,
or hematologic disorder. RCR results were negative, indi-
cating no evidence for in vivo vector persistence.
Conclusion Despite the loss of follow-up, which is the
limiting factor in this long-term safety trial, the findings
from this long-term follow-up study are encouraging.
Key Points
Following the report from a French study in patients
with X-linked severe combined immunodeficiency
(X-SCID), the clinical occurrence of malignancies
due to insertional mutagenesis has raised concerns
about the safety of gene therapy.
Advances in vector research, including the
development of human immunodeficiency virus
(HIV)-1-based lentivectors and new-generation
retroviral (non-replicating) vectors, offer the hope of
developing effective and safe gene therapy
treatment.
This long-term follow-up study of up to 18 years in
adult subjects treated with gene therapy using non-
replicating viral vectors showed no evidence of
vector persistence or insertional mutagenesis related
to gene therapy.
With renewed interest in the use of cell and gene
therapies in a wide variety of debilitating conditions,
the favorable long-term safety profile is highly
encouraging.
1 Introduction
The principle of gene therapy is to achieve efficient
delivery of the relevant genetic material into the target cell
to express the transgene at therapeutic levels [1]. The first
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proof-of-principle gene transfer based on c-retrovirus
transduction was reported almost 20 years ago [2–5]. Early
studies on gene therapy in patients with severe combined
immunodeficiency (SCID) using c-retroviral vectors
showed improvement in disease condition with accept-
able short-term safety profiles. However, these studies were
conducted with an assumption that the potential for inser-
tional activation of an oncogene or insertional inactivation
of a tumor-suppression gene would be minimal [6, 7]. This
assumption was based on the evidence from early animal
studies indicating minimal risk of tumor development with
no reported incidence of vector-induced malignancy in
mice and non-human primates [6]. Furthermore, two
additional studies conducted in patients with X-linked-
SCID in the early 2000s using a retroviral vector showed
substantial improvement in clinical and pathological fea-
tures of the disease condition with no insertional action on
the oncogene or tumor suppressor gene [8, 9]. However, a
study conducted in France wherein patients with X-SCID
were transfused with ex vivo modified hematopoietic cells
with a retroviral vector showed incidence of leukemia in 3
of 11 patients 30 months after gene therapy. This was
believed to be caused by monoclonal T cell expansion and
was determined to be related to the gene transfer product
[10, 11]. It was further observed that retroviral vector
copies were present in the leukemia cells of the two
patients with leukemia, which may have triggered cellular
oncogene at the site of integration by a process known as
‘insertional mutagenesis’. Hence, persistence of integrated
vectors may have contributed to the development of leu-
kemia [12].
Based on the findings from the French study in patients
with X-SCID, the application of retroviral vectors was
believed to be associated with potential risk factors,
including (1) the formation of a replication competent
retrovirus (RCR) as a result of recombination of retroviral
vectors with genomes of the helper cells, infected cells, or
another virus; (2) integration of retrovirus vector in the
vicinity of a growth factor gene/proto-oncogene, leading to
their activation, and increasing the probability of the
development of cancer [13]. The risks associated with
retroviral vector administration eclipsed the clinical benefit
of gene therapy and discouraged their further development
for almost two decades.
Advancements in vector research, including the devel-
opment of human immunodeficiency virus (HIV)-1-based
lentivectors and new-generation retroviral (non-replicating)
vectors (nRCR) designed to reduce the potential of RCR,
and targeted transduction, offered the hope of developing
effective and safe gene therapy treatment [1, 14–16].
Gamma-retroviral vectors used for gene transfer into T
cells have been reported to be safe; no adverse effects from
insertional mutagenesis in any patient infused with T cells
modified with these vectors have been reported [17].
However, subjects exposed to gene transfer technology
may be at risk of delayed adverse events because of per-
sistent biological activity of the genetic material; thus,
long-term follow-up of subjects utilizing this vector is
recommended as per the US FDA 2006 guidance [18].
Chiron Technologies previously conducted 11 studies
using new-generation nRCR-based gene therapy in subjects
with hemophilia (one study), HIV (six studies), and various
malignancies (four studies, including metastatic melanoma,
chronic myelogenous leukemia, chronic lymphocytic leu-
kemia, multiple myeloma) (Table 1). Results from these
studies showed improvement in disease condition with an
acceptable short-term safety profile. However, available
data on the long-term safety profile of nRCR are limited.
The FDA has provided guidance [18] regarding the long-
term follow-up of participants in gene therapy clinical
research. Based on this guidance, integrating vectors (such
as gamma-retrovirus) have the potential to initiate neo-
plastic processes depending upon the site of integration and
the presence of strong promoter/enhancer elements present
in the gene transfer vector. In addition, host characteristics,
such as immune status of the recipient, route of adminis-
tration, and type of cell targeted for transformation, con-
tribute to long-term risk [19].
The objective of the current study was to evaluate the
life-long safety profile of gene therapy using nRCR or cell
products in subjects with hemophilia, HIV, or cancer who
participated in the 11 studies conducted by Chiron
Technologies.
2 Methods
2.1 Study Design and Population
This was a phase II follow-up study (follow-up start date:
June 1998) investigating the long-term safety of subjects
who previously received retroviral vectors or cell products
(active therapy) in any one of 11 Chiron Technologies
Center for Gene Therapy retrovirus treatment protocols.
Table 1 provides details of the gene therapy, vectors used,
and doses and duration of treatment for the enrolled sub-
jects in each of these studies.
As per the present study protocol, subjects were to be
followed-up annually for the duration of the subject’s life
or until the subject was lost to follow-up. Subjects did not
receive any gene therapy during the present long-term
follow-up study. Subjects who became pregnant during the
follow-up study were allowed to continue in the study.
This study was conducted in accordance with the ethical
principles of the Declaration of Helsinki and approved by
the institutional review board or ethics committee at each



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































594 R. Mohanlal et al.
participating site. All subjects provided written informed
consent before enrollment (protocol identification: Chiron
Corporation protocol number CS-GT005/Novartis protocol
number CRV789A2201).
2.2 Safety Evaluations
All serious adverse events (SAEs), including deaths, were
reported. In addition, if an SAE was thought to be related to
vector administration, RCRs were tested via polymerase
chain reaction (PCR) and vector integration studies. Any
unresolved SAEs or toxicities were followed until resolu-
tion or until they were determined to be chronic.
As per the 2006 FDA guidance for cell and gene ther-
apies [18], the incidence of any new malignancy, new
incidence or exacerbation of neurologic disorder, new
incidence or exacerbation of rheumatologic or autoimmune
disorder, or new incidence of hematologic disorder was
considered an SAE of special interest in patients receiving
gene therapies.
2.3 Data Collection
The incidence of SAEs was assessed at 1 year after the last
retroviral vector administration and annually thereafter. In
subjects who completed a 1-year follow-up period in the
original gene therapy study prior to this follow-up study,
the incidence of SAEs was assessed 2 years after the last
dose of vector administration and annually thereafter.
2.4 Blood Collection
Blood samples for banking of peripheral blood mononu-
clear cells (PBMC) for RCR were collected annually for
the duration of the life-long follow-up or until the subject
was deemed lost to follow-up.
For subjects who participated in the vector integration
studies, an additional blood sample was collected and
stored every 6 months during the first 5 years after last
retroviral vector administration and annually during years
6–10 to enable the analysis of clonality of vector integra-
tion sites, if required. In the event of death, an autopsy was
conducted and tissue samples for RCR testing were col-
lected depending on the cause of death and gross findings
on autopsy.
For subjects for whom RCR testing was not performed
in the respective treatment studies, testing for RCR was
planned in the current study.
2.5 Statistical Analysis
We included safety data up to the cut-off date of 31 July
2013 in the analysis for this report. No formal statistical
comparisons were planned for this study. The sample size
was not based on statistical considerations. The analysis
included all enrolled subjects who received active treat-
ment in the previous gene therapy study. The data collected
are summarized and presented by treatment indication:
hemophilia A, cancer, or HIV.
3 Results
3.1 Study Population
The present study included 127 subjects who received
active treatment and 52 subjects who received placebo.
After a protocol amendment, follow-up of the 52 subjects
who received placebo was stopped. On the data cut-off date
of 31 July 2013, of the 127 subjects who previously
received active treatment, 23 remained in the study and 104
had discontinued. The primary reason for discontinuation
was loss to follow-up (47.2 %; n = 60; all from the HIV
group) (Fig. 1). A total of 15 subjects died during the
follow-up study. Loss to follow-up typically occurred
during years 7–10. The majority of subjects enrolled were
from HIV studies (79.5 %; n = 101). Across all studies,
the mean (standard deviation [SD]) age of subjects was 44
(11.0) years, and the majority were men (81.9 %; n = 104)
and Caucasian (88.2 %; n = 112) (Table 2). None of the
female subjects became pregnant during the follow-up. The
median follow-up duration was 6.42 years, and 42
(33.0 %) subjects were followed for a minimum of
10 years. For subjects who received previous active ther-
apy for hemophilia (n = 11), the mean (SD) follow-up
duration was 9.39 (3.53) years (Table 3).
Of the 23 subjects who remained in the study (as of the
data cut-off date), 14 had a safety follow-up between 12
and\15 years and nine subjects had a follow-up of at least
15 years.
3.2 Safety Findings
Overall, 41 subjects experienced at least one SAE
(Table 4). The most frequently reported SAE was pneu-
monia (5.5 %; n = 7). None of the SAEs were considered
by the investigator to be related to the active treatment
received in the original study.
SAEs in the categories of special interest as per the FDA
guidance were reported in 17 subjects who received pre-
vious active treatment and included malignancies (n = 12)
and a neurologic disorder (n = 5). Three subjects with
malignancies also reported other SAEs of special interest:
rheumatologic or autoimmune disorder (n = 1) and
hematologic disorder (n = 2). Of the 12 subjects who
reported malignancies, 11 subjects died (see next
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paragraph) and one subject experienced a non-fatal SAE.
Table 5 presents detailed results for the SAEs of special
interest. None of the SAEs of special interest were con-
sidered by the investigator to be related to the active
therapy administered in the previous gene therapy studies.
Among the subjects who received active treatment in the
previous studies, 15 deaths were reported until the data cut-
off date. None of the deaths were considered by the
investigator to be related to the active treatment adminis-
tered in the previous gene therapy studies. Of the 11 deaths
due to neoplasms, eight were due to progression of the
underlying malignant disease that was the clinical indica-
tion for the initial gene therapy trial in subjects with
malignancy (metastatic malignant melanoma [n = 3],
chronic lymphocytic leukemia [n = 2], malignant mela-
noma [n = 1], metastatic neoplasm [n = 1], plasma cell
Fig. 1 Subject disposition in
the long-term safety follow-up
study. Single asterisk subjects
receiving placebo in the Chiron
Technologies studies were not
followed-up as per protocol
amendment. Double asterisks
subjects lost to follow-up were
from HIV studies. Hash subjects
who remained in the study at the
data cut-off date of 31 July
2013. HIV human
immunodeficiency virus
Table 2 Demographics of
subjects enrolled in the long-
term safety follow-up study
Indication/disease Hemophilia A, n = 11 Cancer, n = 15 HIV, n = 101 Total, N = 127
Mean age, years (SD) 39.5 (15.6) 56.1 (14.9) 42.7 (8.4) 44.0 (11.0)
Sex
Male 11 (100.0) 9 (60.0) 84 (83.2) 104 (81.9)
Female 0 6 (40.0) 17 (16.8) 23 (18.1)
Race
Caucasian 10 (90.9) 12 (80.0) 90 (89.1) 112 (88.2)
Black 1 (9.1) 1 (6.7) 3 (3.0) 5 (3.9)
Other 0 2 (13.3) 8 (7.9) 10 (7.9)
Data are presented as n (%) unless otherwise indicated
HIV human immunodeficiency virus
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myeloma [n = 1]). In one subject with underlying meta-
static malignant melanoma, death was due to development
of metastatic pancreatic carcinoma that was diagnosed
8.5 years after the last dose of study drug in the previous
gene therapy study CS-GT004. In two other cases, one
death was due to new malignancies that developed in
subjects with HIV–Kaposi’s sarcoma, and the other death
was due to malignant lung neoplasm (Table 5). The subject
who died because of Kaposi’s sarcoma did so 3.26 years
after the last dose of gene therapy administered in the
previous study (VHII-01) for the treatment of HIV.
Kaposi’s sarcoma was confirmed by the examination of
lesions on the subject’s skin. Likewise, the subject with
malignant lung neoplasm had a history of tobacco use and
died 5 years after the last retroviral vector administration in
the previous study (HIV-03-393) for the treatment of HIV.
Two neurological disorders led to deaths:
encephalopathy (n = 1) in a subject with HIV, and
intracranial hemorrhage (n = 1) in a subject with
hemophilia.
The remaining two deaths occurred outside the SAEs of
special interest: cardiac arrest (n = 1) and suicide (n = 1).
In the initial active-treatment study, RCR data were
obtained from 127 subjects. All RCR results obtained in the
initial studies were negative, except a transient positive test
in the seminal fluid of one subject from the hemophilia
study. This subject had a single transiently positive PCR
test for the retroviral vector in his semen on day 55. Repeat
tests on days 75, 82, 96, and 110 were negative. Of note,
this subject participated in the current follow-up study and
had not experienced any SAEs up to the data cut-off date of
31 July 2013. None of the SAEs reported in this long-term
Table 3 Study duration (all
subjects)
Hemophilia A, n = 11 Oncology, n = 15 HIV, n = 101 Total, N = 127
Study duration, years
Mean (SD) 9.4 (3.5) 5.5 (4.8) 7.1 (4.9) 7.1 (4.9)
Median 10.8 4.3 6.3 6.4
Range 2.01–11.98 0.03–13.21 0.59–15.11 0.03–15.11
Study duration, years, n (%)
\3 1 (9.1) 6 (40.0) 27 (26.7) 34 (26.8)
3 to\6 2 (18.2) 3 (20.0) 22 (21.8) 27 (21.3)
6 to\9 0 1 (6.7) 17 (16.8) 18 (14.2)
9 to\10 0 2 (13.3) 4 (4.0) 6 (4.7)
10 to\11 3 (27.3) 0 4 (4.0) 7 (5.5)
11 to\12 5 (45.5) 0 4 (4.0) 9 (7.1)
12 to\13 0 1 (6.7) 3 (3.0) 4 (3.1)
C13 0 2 (13.3) 20 (19.8) 22 (17.3)
HIV human immunodeficiency virus, SD standard deviation
Table 4 Most frequently (n C 2) reported serious adverse events during the long-term safety follow-up study
Preferred term Hemophilia, n = 11 Oncology, n = 15 HIV, n = 101 Total, N = 127
Subjects with SAE(s) 7 (63.6) 11 (73.3) 23 (22.8) 41 (32.3)
Pneumonia 1 (9.1) 3 (20.0) 3 (3.0) 7 (5.5)
Dehydration 0 0 4 (4.0) 4 (3.1)
Appendicitis 0 0 3 (3.0) 3 (2.4)
Metastatic malignant melanoma 0 3 (20.0) 0 3 (2.4)
Deep vein thrombosis 0 2 (13.3) 1 (1.0) 3 (2.4)
Diarrhea 0 0 2 (2.0) 2 (1.6)
Sepsis 1 (9.1) 1 (6.7) 0 2 (1.6)
Influenza 1 (9.1) 1 (6.7) 0 2 (1.6)
Depression 0 0 2 (2.0) 2 (1.6)
Suicide attempt 0 0 2 (2.0) 2 (1.6)
Myocardial infarction 0 1 (6.7) 1 (1.0) 2 (1.6)
Data are presented as n (%)
HIV human immunodeficiency virus, SAE serious adverse event
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safety protocol were considered to be related to the study
drug; therefore, no DNA samples were required to be
analyzed by PCR for RCR as per the protocol. However,
testing was performed in 20 subjects who entered in the
present long-term safety study without completing the first
year follow-up of the active treatment study; the results
were negative for RCR.
4 Discussion
This study evaluated the long-term safety and evidence of
vector persistence in subjects who were followed for up to
18 years after treatment with nRCRs or ex vivo retroviral
vector gene-transduced cell products. With a renewed
interest in the use of cell and gene therapies in a wide
variety of debilitating conditions [20], the long-term safety
findings reported here are of paramount importance and
highly encouraging. The negative RCR findings in the
present study suggests lack of in vivo vector persistence
during the long-term follow-up. In addition, investigators
deemed the SAEs, including death, reported in this study
not related to the active gene therapy. Although the findings
cannot be generalized to conclude that all gene therapies are
safe, this study is one of the early reports to provide insight
into the long-term safety of gene-transduced cell products.
Two major safety concerns with use of retroviral vectors
include the risk of insertional mutagenesis with increased
Table 5 Incidence of serious adverse events of special interest (as defined by the US FDA for cell and gene therapies) reported during the long-
term safety follow-up study








Neoplasms benign, malignant and unspecified (including cysts and
polyps)
0 8 (53.3) 3 (3.0) 11 (8.7)
Metastatic malignant melanomac 0 3 (20.0) 0 3 (2.4)
Chronic lymphocytic leukaemiac,d 0 1 (6.7) 0 1 (0.8)
Kaposi’s sarcomac 0 0 1 (1.0) 1 (0.8)
Lung neoplasm malignantc 0 0 1 (1.0) 1 (0.8)
Malignant melanomac 0 1 (6.7) 0 1 (0.8)
Metastases to lung 0 0 1 (1.0) 1 (0.8)
Metastatic neoplasmc 0 1 (6.7) 0 1 (0.8)
Pancreatic carcinomac 0 1 (6.7) 0 1 (0.8)
Plasma cell myelomac 0 1 (6.7) 0 1 (0.8)
Renal cell carcinoma 0 0 1 (1.0) 1 (0.8)
Nervous system disorders 2 (18.2) 0 2 (2.0) 4 (3.1)
Carotid artery stenosis 1 (9.1) 0 0 1 (0.8)
Haemorrhage intracranialc,e 1 (9.1) 0 0 1 (0.8)
Neuralgia 0 0 1 (1.0) 1 (0.8)
Neuropathy peripheral 0 0 1 (1.0) 1 (0.8)
Syncope 0 0 1 (1.0) 1 (0.8)
Immune system disorders 0 1 (6.7) 0 1 (0.8)
Drug hypersensitivity 0 1 (6.7) 0 1 (0.8)
Blood and lymphatic system disorders 0 2 (13.3) 0 2 (1.6)
Febrile neutropenia 0 1 (6.7) 0 1 (0.8)
Pancytopenia 0 1 (6.7) 0 1 (0.8)
Data are presented as n (%)
CLL chronic lymphocytic leukemia, HIV human immunodeficiency virus, SAEs serious adverse events
a This classification of the events was based on primary System Organ Class from the Medical Dictionary for Regulatory Activities
b In this table, one subject may have experienced more than one event. This table was generated automatically from the clinical database
c These SAEs of special interest resulted in death in 13 cases
d An additional subject who died from CLL is not reflected in this table as this single death was documented from another source and is therefore
included in the text only (total CLL, n = 2)
e An additional subject who died from encephalopathy is not reflected in this table as this single death was documented from another source and
is therefore included in the text only
598 R. Mohanlal et al.
probability of subsequent malignancy and the possibility of
generating RCR [16]. Following the report from the French
study on the development of new malignancy in three
children with X-SCID after exposure to a retroviral vector
[10, 11], the FDA provided specific recommendations on
the long-term monitoring of patients participating in stud-
ies utilizing products derived from either gamma-retro-
viruses or lentiviruses [21]. The SAEs of special interest as
outlined in the FDA guidance include new malignancies,
new incidence or exacerbation of neurologic disorder, new
incidence or exacerbation of rheumatologic or autoimmune
disorder, and new incidence of hematologic disorder [18].
The present study found no indication of emergence of
any new safety signals of neurologic disorders, rheumato-
logical or autoimmune disorders, or hematologic disorders.
Development of new malignancies was identified in four
subjects; three were fatal and one was non-fatal. Two of the
three fatal cases were in subjects who received gene ther-
apy for the treatment of HIV. In one case, the patient
developed Kaposi’s sarcoma, which was diagnosed
20 months after the last dose of active treatment. In the
second HIV patient, malignant lung neoplasm was diag-
nosed 5 years after the last dose of active treatment. The
third fatal case was a subject who was treated with gene
therapy for multiple myeloma and developed metastatic
pancreatic carcinoma 8.5 years after the last dose of active
treatment. The non-fatal case was in a HIV patient who
developed renal cell carcinoma and metastases to the lung,
both of which were diagnosed 3 years after the last dose of
active therapy. The investigator did not consider any of
these events to be related to the previous study treatment.
Assessment of these critically ill subjects is particularly
difficult because of complications from the underlying
disease. Three of these four subjects had confounding
factors relating to the complications of the underlying
disease. For example, Kaposi’s sarcoma is predominantly
associated with HIV [22], and the patient who developed a
malignant lung neoplasm had a history of tobacco use.
Likewise, renal cell carcinoma is also associated with HIV
[23].
Moloney murine leukemia retrovirus (MLV-RV) con-
taining the corrective gene cc utilized in the X-SCID trial
raised some concerns related to genotoxic risk associated
with uncontrolled insertion into the genome of
CD34 ? hematopoietic stem/progenitor cells [10].
Uncontrolled insertion of the retrovirus resulted in the copy
of the vector DNA found in the growth-promoting gene or
near the proto-oncogene, i.e., genes known to regulate
stem-cell proliferation. This resulted in T-cell leukemia in
the X-SCID patients between 3 and 6 years after gene
therapy [10, 16]. As with the X-SCID trial, insertional
oncogenesis was also reported in early trials in patients
with Wiskott Aldrich syndrome (WAS) and chronic
granulomatous disease (CGD) using retroviral vector
[24–26]. However, such adverse events were not reported
with MLV-RV used to treat adenosine deaminase (ADA)-
SCID [27]. Analysis of the mechanisms of retroviral inte-
gration and mutagenesis suggest that the likelihood of
mutagenesis may be affected by other factors, such as
underlying disease, cell type, and transgene or specific
vector and transduction characteristics [8, 11, 28]. More-
over, the authors of the WAS trial opined that the relatively
high vector copy number per cell, in addition to the disease
background, may have contributed to the increased risk of
insertional mutagenesis [24]. These findings prompted the
development of safer vector constructs based on self-in-
activating (SIN) retroviral or lentiviral vectors (LVs) [29].
The retroviral vectors used in the 11 Chiron studies
lacked the coding sequences to generate replication while
retaining the elements required for efficient reverse tran-
scription, integration, or transcription in the transduced host
cell. In addition, Southern blot analysis of human genomic
DNA failed to demonstrate any significant homology with
Moloney virus. Also, unlike X-SCID [6]—which is a single
inherited gene disorder (mutation of cc-encoding gene)
occurring in infants/young children where retroviral vectors
were used for the integration of the functional copy of cc
gene into the genome of CD34? hematopoietic stem/pro-
genitor cells [30]—the Chiron gene therapy products were
used in adults for the treatment of HIV, cancer, or hemo-
philia (11 studies). Furthermore, the gene therapies were
either injected directly into the tumor, administered as
intramuscular or intravenous injections, or used to transfect
PBMCs that were non-stem cell in origin. With direct intra-
tumor, intramuscular, or intravenous injection, no selective
transduction of hematopoietic cells is possible, thus low-
ering the probability of stem- cell transfection. Likewise,
production of renewable cell populations with ex vivo
transfection of PBMCs is highly unlikely because (1) non-
mobilized PBMCs contain very few stem cells; (2) the cell
expansion using anti-CD3 antibody is very specific to the T
cells and does not affect stem cells, and (3) mature T cells
have limited potential for division and disappear over time.
Thus, the lack of oncogenic effect in our study may be
attributed to the differences in the patients treated, age of
patients, cell type (non-stem cell), vector (different from
Moloney virus), or transduction characteristics compared
with the X-SCID trial.
RCR could conceivably be produced by recombination
in vivo. However, given the product characteristics of the
Chiron gene therapies—i.e., lacking the coding sequences
to replicate and the very low probability of stem cell
transduction—the duration of in vivo vector persistence
can be expected to be relatively short. Indeed, both in the
active treatment study prior to long-term follow-up (in 127
subjects) and in the long-term follow-up study (in 20
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subjects), the RCR results were negative. The favorable
safety profile and the absence of RCR in the current study
further support the short vector persistence.
Our study had several limitations. The original study
trials using gene therapy were conducted in a heterogeneous
population of adults with HIV, cancer, or hemophilia. These
disorders in themselves are a major confounding issue in
identifying the cause of adverse events or any subsequent
mortality. The sample size in this study was not based on
any statistical considerations: all patients receiving active
therapy in any of the 11 active treatment Chiron Tech-
nologies studies were enrolled in the long-term follow-up
study. Although 127 subjects who received gene therapy
were enrolled in the long-term follow-up study in June
1998, at the time of data cut-off in July 2013, only 23
subjects remained in the study. The remaining 104 subjects
had discontinued, including 60 subjects who were lost to
follow-up. Thus, the number of subjects under observation
at the end of the 18-year follow-up interval is likely to be
too small to allow definite conclusions on the long-term
safety of the viral vector. Moreover, although we studied
vector persistence by RCR, we did not study persistence of
the transduced cells or conduct any karyotype assessment
(beyond RCR) during the long-term follow-up, which fur-
ther limits any definite conclusions on long-term safety. The
author of a recent review on progress in gene therapy
highlighted data from several clinical trials on gene thera-
pies conducted in infants/children or adults in various
indications that used lentiviral, gamma-retroviral, or adeno-
associated virus as vectors for transduction [31]. Among the
studies listed, very few had at least 3-year follow-up data,
and only one study had data for up to 8 years of follow-up.
The author contends that, in any given trial, the actual risk
of genotoxicity is difficult to establish because of the low
number of patients treated, the longer follow-up period
needed, and possibility of the disease itself increasing the
risk [31]. The findings of the present study cannot be gen-
eralized to all gene therapies utilizing retroviral vectors. A
high number of patients were lost to follow-up in our study.
Nevertheless, the follow-up period for the 60 subjects lost to
follow-up was between 7 and 10 years, and annual exami-
nations in these subjects up to 5 years [21] did not show any
adverse outcomes related to retroviral-based gene therapy,
suggesting a lack of in vivo viral persistence in these
subjects.
5 Future Implications
Over the past decade, efforts to ensure development of a
safer vector system with a reduced potential for insertional
mutagenesis have led to the development of SIN gamma-
retroviral vector [32–35]. Moreover, no recorded cases of
insertional mutagenesis have been reported in studies that
utilized retroviral gene transduction in subjects with HIV
[36].
Developments in vector systems have also led to the
introduction of lentiviruses that are potent and versatile
vectors for ex vivo or in vivo gene transfer into dividing
and non-dividing cells [37]. Lentivirus also belong to the
retrovirus family; however, several changes have been
made to their genome to maximize safety and minimize the
risk of generating replication-competent wild-type HIV-1
recombinants [37, 38]. Separation of the transducing vector
from the packaging plasmids in the HIV-1-based lentivirus
decreases the generation of replication-competent len-
tivirus (RCL) [37, 39]. These improvements in molecular
constructs for LV generation mean the probability of RCL
recombinants is extremely low [40]. To our knowledge, no
such cases have yet been reported [41]. Moreover, len-
tiviruses differ in their integration profile from gamma-
retroviruses, and the absence of a long-terminal repeat
promotor in the integrated pro-virus of modern-generation
SIN lentiviruses make them less genotoxic [39]. In a phase
I open-label nonrandomized controlled trial for HIV uti-
lizing LVs for gene transduction, no evidence for inser-
tional mutagenesis was reported after 21–36 months of
observation [42].
The ability of LVs to transduce non-dividing cells
means they have a wide variety of applications that are
undergoing clinical testing in many genetic disorders.
These include the treatment of beta-thalassemia,
adrenoleukodystrophy, Parkinson’s disease, Wiskott–
Aldrich syndrome, acquired immunodeficiency syndrome,
and cancer [37, 38]. One such advance in cancer therapy is
the use of genetically modified T cells via LVs or retroviral
vectors for ex vivo transduction of patient T cells with
chimeric antigen receptor (CAR) sequence to stably
express a fragment of an antibody on their surface, con-
ferring new antigen specificity to target several malignan-
cies [38]. CD19 is one such target expressed on most B-cell
malignancies, and CAR therapies targeting CD19-specific
malignancies have reported high response rates in hema-
tological malignancies such as acute lymphoblastic leuke-
mia (ALL) [43].
CTL019 is a CAR T therapy of autologous T cells
genetically modified to target CD19 through transduction
with an LV expressing anti-CD19 linked to CD3-zeta and
CD137 (4-1BB) signaling domains [43, 44]. In patients
with relapsed or refractory ALL, CTL019 was associated
with a high remission rate (90 %)—even among patients
for whom stem-cell transplantation had failed—and dur-
able remissions up to 24 months were observed [45]. The
probability of persistence of CTL019 was 68 % at
6 months. Prolonged persistence for as long as 2 years in
patients with ALL and as long as 3 years in patients with
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chronic lymphocytic leukemia (CLL) has been reported
[45, 46]. This persistence of CTL019 is thought to provide
a continued clinical benefit. Current safety data in patients
monitored in these studies (up to 24 months) have not
reported any concerns on insertional mutagenesis [44, 45].
For any gene therapy with persistent biological activity,
the potential for delayed adverse events is currently con-
sidered high [21]. LVs, as with gamma-retrovirus and
herpesvirus, are considered to pose a high risk of delayed
adverse events, and the FDA recommends long-term fol-
low-up observational studies to mitigate any potential long-
term risks to subjects receiving these vectors [18, 21, 40].
Based on the FDA guidance, long-term follow-up obser-
vational studies for up to 15 years are planned for all
CTL019 studies.
6 Conclusions
Follow-up of all subjects in the Chiron Technologies
studies who received gene therapies using non-replicating
gamma-retroviral vectors for transduction for at least
7 years, with 12–18 years of long-term safety data avail-
able for one-fifth of these subjects, found no evidence of
vector persistence or insertional mutagenesis related to
gene therapy. Although the findings cannot be generalized
to conclude that all gene therapies are safe, this study is one
of the early reports to provide insight into the long-term
safety of gene-transduced cell products. With the renewed
interest in the use of cell and gene therapies in a wide
variety of debilitating conditions, the favorable long-term
safety profile is highly encouraging. CTL019, a CAR T
therapy, is a genetically modified T-cell therapy targeting
CD19 that utilizes LVs for transduction. Safety data for up
to 2 years in patients using CTL019 have not indicated any
concerns with the use of LVs, and long-term follow-up
observational studies for up to 15 years are planned for all
CTL019 studies.
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